Identification and Characterization of the Ocular Hypotensive Efficacy of Travoprost, a Potent and Selective FP Prostaglandin Receptor Agonist, and AL-6598, a DP Prostaglandin Receptor Agonist

References 

1. Alm A, Villmsen J. Effects of topically applied PGF_2α and its isopropyl ester on normal and glaucomatous human eyes. In:  Bito L,  Stjernschantz J editor. The Ocular Effects of Prostaglandins and Other Eicosanoids. New York: Alan Liss Inc; 1989;p. 447–458
2. Bito LZ, Baroody RA. The ocular pharmacokinetics of eicosanoids and their derivatives 1. Comparison of ocular eicosanoid penetration and distribution following the topical application of PGF_2α, PGF_2α 1-methyl ester and PGF2a α-1-isopropyl ester. Exp Eye Res. 1987;44:217–226
   • MEDLINE
   • CrossRef
3. Crider JY, Griffin BW, Sharif NA. Prostaglandin DP receptors positively coupled to adenylyl cyclase in embryonic bovine tracheal (EBTr) cells (pharmacological characterization using agonists and antagonists). Br J Pharmacol. 1999;127:204–210
   • MEDLINE
   • CrossRef
4. Crider JY, Xu SX, Griffin BW, Sharif NA. Use of a semi-automated, robotic radioimmunoassay to measure cAMP generated by activation of DP-, EP₂- and IP-prostaglandin receptors in human ocular and other cell-types. Prostaglandins Leukotrienes & Essential Fatty Acids. 1998;59:77–82
5. Flach A, Eliason J. Topical prostaglandin E₂ effects on normal human intraocular pressure. J Ocular Pharm. 1988;4:13–18 [Published erratum appears in J Ocul Pharmacol 7:189, 1991 which correctly identifies the compound evaluated as EP analog RS-18492]
6. Goh Y, Nakajim M, Azuma I, Hayashi O. Effects of prostaglandin D₂ and its analogues on intraocular pressure in rabbits. Jpn J Ophthalmol. 1988;32:471–480
   • MEDLINE
7. Goh Y, Nakajim M, Azuma I. Prostaglandin D₂ reduces intraocular pressure. Br J Ophthalmol. 1988;72:461–464
   • MEDLINE
   • CrossRef
8. Guiffre G. The effects of prostaglandin F_2α in the human eye. Graefes Arch Clin Exp Ophthalmol. 1985;222:139–141
   • MEDLINE
   • CrossRef
9. Hackett RB, McDonald TO. Eye irritation. In:  Marzulli FN,  Maibach HI editor. Dermatotoxicology. Washington DC: Hemisphere Publishing Corp; 1991;p. 299–306 ed 4,
10. Hellberg MR, Sallee VL, McLaughlin MA, et al.  Preclinical efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist. J Ocul Pharmacol Ther. 2001;17:421–432
    • MEDLINE
    • CrossRef
11. Liljebris C, Solen G, Resul B, et al.  Derivatives of 17-phenyl-18,19,20-trinorprostaglandin F_2α isopropyl ester (potential antiglaucoma agents). J Med Chem. 1995;38:289–304
    • MEDLINE
    • CrossRef
12. Matsugi T, Kageyama M, Nishimura K, et al.  Selective prostaglandin D₂ receptor stimulation elicits ocular hypotensive effects in rabbits and cats. Eur J Pharmacol. 1995;275:245–249
    • MEDLINE
    • CrossRef
13. Nakajima M, Goh Y, Azuma Hayashi O. Effects of prostaglandin D₂ and its analogue, BW245C on intraocular pressure in humans. Graefes Arch Clin Exp Opthalmol. 1991;229:411–413
14. Netland PA, Landry T, Sullivan EK, et al.  Travoprost compared with latanoprost and timolol, in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2001;132:472–484
    • Abstract
    • Full Text
    • Full-Text PDF (185 KB)
    • CrossRef
15. Resul B, Stjernschantz J, No K, et al.  Phenyl-substituted prostaglandins (potent and selective antiglaucoma agents). J Med Chem. 1993;36:243–248
    • MEDLINE
    • CrossRef
16. Resul B, Stjernschantz J, Selen G, Bito L. Structure-activity relationships and receptor profiles of some ocular hypotensive prostanoids. Surv Opthalmol. 1997;41(Suppl 2):S47–S52
17. Schulz BG, Beckman R, Muller B, et al.  Cardio- and hemodynamic profile of selective PGD₂ analogs. Adv Prostaglandin Thromboxane Leukotriene Res. 1991;21:591–594
18. Sharif NA, Crider JY, Xu SX, Williams GW. Affinities, selectivities, potencies and intrinsic activities of natural and synthetic prostanoids using endogenous receptors (focus on DP class prostanoids). J Pharmacol Exp Ther. 2000;293:321–328
    • MEDLINE
19. Sharif NA, Davis TL, Williams GW. [³H]AL-5848 ([³H] 9β-(+)-Fluprostenol). Carboxylic acid of travoprost (AL-6221), a novel FP prostaglandin to study the pharmacology and autoradiographic location of the FP receptor. J Pharm Pharmacol. 1999;51:685–694
    • MEDLINE
    • CrossRef
20. Stjernschantz J, Resul B. Phenyl substituted prostaglandin analogues for glaucoma treatment. Drugs of the Future. 1992;17:691–704
21. Stjernschantz J, Selen G, Sjoquist B, Resul R. Preclinical pharmacology of latanoprost, a phenyl-substituted PFG2 alpha analogue. Adv Prostaglandin Thromboxane Leukotriene Res. 1995;23:513–518
22. Thierauch KH, Sturzebecher S, Schillinger E, et al.  Stable 9β or 11α halogen-15-cyclohexyl-prostaglandins with high affinity to the PGD₂ receptor. Prostaglandins. 1988;35:855–868
    • MEDLINE
    • CrossRef
23. Waterbury L, Eglen R, Faurot G, Cooper G. EP₃ but not EP₂, FP, or TP prostanoid-receptor stimulation may reduce intraocular pressure. Invest Ophthalmol Vis Sci. 1990;31:2560–2567
    • MEDLINE
24. Woodward D, Chan M, Burke J, et al.  J Ocular Pharmacol Ther. 1994;10:177–193
25. Woodward DF, Hawley SB, Williams LS, et al.  Studies on the ocular pharmacology of prostaglandin D₂. Invest Ophthalmol Vis Sci. 1990;31:138–146
    • MEDLINE
26. Woodward DF, Spada CS, Hawley SB, et al.  Further studies on ocular responses to DP receptor stimulation. Eur J Pharmacol. 1993;230:327–333
    • MEDLINE
    • CrossRef
27. Zhan GF, Toris CB, Camras CB, et al.  A prostaglandin DP receptor agonist increases uveoscleral outflow in normotensive monkey eyes. Invest Ophthalmol Vis Sci (Suppl). 2001;42S:4502; [abstract]